Chimeric monoclonal antibodies recognizing human interleukin-2-receptor
AssigneeBayer Aktiengesellschaft
InventorsTibor Diamantstein, Hisao Osawa
Life of this patent
Estimating the term…
Abstract
Two chimeric monoclonal antibodies are disclosed which recognize the human interlukin-2-receptor and are capable of inhibiting interlukin-2 dependent lymphocyte proliferation. The antibodies comprise the variable regions of monoclonal antibodies AHT-54 or AHT-107 linked to a human Fe region.
Claims2
A chimeric mouse-human monoclonal antibody that specifically binds to the human interleukin-2 receptor, wherein the variable region of said antibody is identical to that of monoclonal antibody AHT-54 produced by the hybridoma deposited under accession number ECACC 86041801 and the Fc region of said antibody is obtained from a human antibody.
A chimeric mouse-human monoclonal antibody that specifically binds to the human interleukin-2 receptor, wherein the variable region of said antibody is identical to that of monoclonal antibody AHT-107 produced by the hybridoma deposited under accession number ECACC 86041802 and the Fc region of said antibody is obtained from a human antibody.
Dependencies are inferred from the claim text.